Results 101 to 110 of about 9,532 (171)

Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study. [PDF]

Blood Cancer J
Pasvolsky O, Costa BA, Aljawai YM, Patel KK, Bashir Q, Sui D, Srour SA, Tanner MR, Popat UR, Saini NY, Hosing C, Ramdial JL, Lee HC, Kaufman GP, Thomas SK, Weber DM, Becnel M, Tang G, Orlowski RZ, Champlin RE, Nieto Y, Shpall EJ, Qazilbash MH.   +22 more
europepmc   +1 more source

Real-world efficacy and safety of the carfilzomib-pomalidomide-dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study. [PDF]

Ther Adv Hematol
Fan H, Feng X, Wei R, Zhang X, Li T, Liu L, Wang H, Sun L, Shi X, Zhao H, Li Z, Cui J, Xu J, Ma J, Feng X, Wang W.   +15 more
europepmc   +1 more source

Orelabrutinib in combination with pomalidomide for the successful treatment of primary vitreoretinal lymphoma: a case report. [PDF]

Front Med (Lausanne)
Lai Y, Lin P, Sheng L, Ouyang G, Li B, Wu N, You S.   +6 more
europepmc   +1 more source

Efficacy and Safety of Immune Checkpoint Inhibitors in the Treatment of Hematologic Malignancies: An Umbrella Review of Systematic Reviews and Meta-Analyses. [PDF]

Cancer Med
Yu Z, Wang Z, Xie L, Xu J, Min L, Li L, Niu T.   +6 more
europepmc   +1 more source

Retreatment with talquetamab and pomalidomide in triple-class-BCMA-GPRC5D refractory myeloma. [PDF]

Br J Haematol
Rahbari KJ, Galarza Fortuna GM, Dholaria B, Sborov DW, Baljevic M.   +4 more
europepmc   +1 more source

Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial. [PDF]

Br J Haematol
Hall A, Croft J, Walker K, Boyd K, Roberts S, Holroyd A, Garg M, Ferris E, Cook G, Pierceall WE, Thakurta A, Gandhi A, Pawlyn C, Brown SR, Kaiser M.   +14 more
europepmc   +1 more source

Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma. [PDF]

Cancer
Worth HA, Costa LJ.
europepmc   +1 more source

Binding Modes of Thalidomide Derivatives in Cereblon-Neosubstrate Complexes Revealed by Molecular Dynamics and Free Energy Calculations. [PDF]

ACS Omega
Martín V, Andjelkovic M, Barrientos C, Leon I, Tuñón I.   +4 more
europepmc   +1 more source

Characteristics associated with clinical response to pomalidomide in hereditary hemorrhagic telangiectasia. [PDF]

Blood Adv
Al-Samkari H, Thomas SM, Marsh D, Kasthuri RS, Iyer VN, Pishko AM, Decker JE, Weiss CR, Whitehead KJ, Conrad MB, Zumberg MS, Zhou JY, Parambil J, Carper B, Clancy M, McCrae KR.   +15 more
europepmc   +1 more source

Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third-Line or Later Relapsed/Refractory Multiple Myeloma. [PDF]

Am J Hematol
Richter J, Efebera Y, Yimer H, Shukla P, Kapetanakis V, Purser M, Boytsov N, Ballew N.   +7 more
europepmc   +1 more source